FABP4 and hepatocellular carcinoma: Although FABP4 and FABP5 demonstrate opposite expression levels in HCC tissues and serum, these proteins are promising biomarkers and therapeutic targets in HCC, as their dysregulation reflects the metabolic dependency of liver cancer on fatty acid synthesis and utilization.